Taming the cytokine storm: repurposing montelukast for the attenuation and prophylaxis of severe COVID-19 symptoms.
Drug Discov Today
; 25(12): 2076-2079, 2020 12.
Article
in English
| MEDLINE | ID: covidwho-778755
ABSTRACT
As a result of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, a clinical complication can arise that is characterized by a hyperinflammatory cytokine profile, often termed a 'cytokine storm'. A protein complex (nuclear factor kappa-light-chain-enhancer of activated B cells; NF-κB) is intricately involved in regulating inflammation and the immune response following viral infections, with a reduction in cytokine production often observed following a decrease in NF-κB activity. An approved asthma drug, montelukast, has been found to modulate the activity of NF-κB, and result in a corresponding decrease in proinflammatory mediators. Herein, we hypothesize that repurposing montelukast to suppress NF-κB activation will result in an attenuation of proinflammatory mediators and a decrease in cytokine production, thereby leading to a reduction in symptom severity and to improved clinical outcomes in patients with Coronavirus 2019 (COVID-19).
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Quinolines
/
Respiratory Distress Syndrome
/
Cytokines
/
NF-kappa B
/
Leukotriene Antagonists
/
Cytokine Release Syndrome
/
COVID-19 Drug Treatment
/
Acetates
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Drug Discov Today
Journal subject:
Pharmacology
/
Drug Therapy
Year:
2020
Document Type:
Article
Affiliation country:
J.drudis.2020.09.013
Similar
MEDLINE
...
LILACS
LIS